ArticleMateria socio-medica2025
Association Between HLA-A*02:07 and Fixed Drug Eruption Caused by Sulfamethoxazole-Trimethoprim.
Article in Materia socio-medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Etoricoxib-Induced Fixed Erythema.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fixed drug eruption (FDE) is an adverse drug reaction that recurs at the same site upon re-exposure to the triggering medication. Sulfonamide antibiotics, especially sulfamethoxazole-trimethoprim, are common causes of FDE. Previous studies have linked drug hypersensitivity reactions to specific human leukocyte antigens (HLA). Objective: This study aimed to investigate the association between HLA-A and FDE induced by sulfamethoxazole-trimethoprim. Methods: A cross-sectional study was conducted with 30 FDE patients and 30 healthy controls who had tolerated sulfamethoxazole-trimethoprim. Blood samples (3 ml) were collected for HLA-A typing using polymerase chain reaction with sequence-specific oligonucleotides (PCR-SSO). Results: Twenty-three HLA-A alleles were detected. In the FDE group, the alleles with high frequency were HLA-A*02:07 (12 patients; 40%), HLA-A*11:01 (10 patients; 33.3%), and HLA-A*24:02 (6 patients; 20%). In the control group, the most commonly observed alleles were HLA-A*11:01 (12 patients; 40%), HLA-A*24:02 (6 patients; 20%), HLA-A*24:07 (6 patients; 20%), HLA-A*29:01 (6 patients; 20%), and HLA-A*33:03 (9 patients; 30%). The FDE group had a higher frequency of HLA-A*02:07 than the control group (40% vs. 16.67%, p < 0.05). No differences in the frequencies of other HLA-A alleles were observed between the two groups. Participants with the HLA-A*02:07 allele were 3.33 times more likely to develop FDE caused by sulfamethoxazole-trimethoprim compared to those without the allele (OR = 3.33, 95% CI: 1.09 - 11.14). Conclusion: The study suggests an association between the HLA-A*02:07 allele and FDE induced by sulfamethoxazole-trimethoprim in the Vietnamese population. Screening for HLA-A*02:07 prior to prescribing sulfamethoxazole-trimethoprim could help identify at-risk individuals and prevent FDE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.